Cargando…

Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study

BACKGROUND: Within the Brazilian Unified Health System (SUS), Referral Centers (RCs) are care facilities that provide specialized services. The objective of this study was to evaluate the efficacy of care provided to patients with multiple myeloma (MM) at a specialized RC (Hospital de Clínicas de Po...

Descripción completa

Detalles Bibliográficos
Autores principales: Saccilotto, Indara C., Bittencourt, Rosane Isabel, Fischer, Camila C., Quevedo, Amanda, Hirakata, Vania N., Picon, Paulo D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595122/
https://www.ncbi.nlm.nih.gov/pubmed/26438377
http://dx.doi.org/10.1186/s12913-015-1123-6
_version_ 1782393542338936832
author Saccilotto, Indara C.
Bittencourt, Rosane Isabel
Fischer, Camila C.
Quevedo, Amanda
Hirakata, Vania N.
Picon, Paulo D.
author_facet Saccilotto, Indara C.
Bittencourt, Rosane Isabel
Fischer, Camila C.
Quevedo, Amanda
Hirakata, Vania N.
Picon, Paulo D.
author_sort Saccilotto, Indara C.
collection PubMed
description BACKGROUND: Within the Brazilian Unified Health System (SUS), Referral Centers (RCs) are care facilities that provide specialized services. The objective of this study was to evaluate the efficacy of care provided to patients with multiple myeloma (MM) at a specialized RC (Hospital de Clínicas de Porto Alegre Referral Center for Multiple Myeloma, CRMM-HCPA) and to compare quality of life between patients with MM treated at CRMM-HCPA and those treated at non-RC facilities. METHODS: A 6-month cohort study was conducted in patients with MM receiving thalidomide from the Rio Grande do Sul State Health Department and treated at CRMM-HCPA and patients receiving treatment at other, non-RC care facilities. Thirty-two patients were included in the study, 19 from CRMM-HCPA and 13 from other institutions. To analyze the efficacy of care provided at CRMM-HCPA, the main outcome measure was the time from diagnosis to referral for autologous hematopoietic stem cell transplantation (HSCT). This outcome measure was assessed using questionnaires specifically designed for this study. Quality of life was also assessed, using the SF-36 questionnaire. RESULTS: Time from MM diagnosis to referral for autologous HSCT in each group was measured only in patients aged ≤ 65 years (n = 25); of these, 15 were recruited from CRMM-HCPA and 10 from other institutions. In this analysis, there was a significant difference (p = 0.036) in time elapsed between diagnosis and referral for autologous HSCT, which was significantly shorter for patients treated at CRMM-HCPA (median, 9 months; IQR, 8.5–14.5) than for those treated elsewhere (median, 24 months; IQR, 16–24). On quality of life analysis, there was a significant difference in the Social Functioning domain of the SF-36 questionnaire, which relates to performance of social activities (p = 0.02). CONCLUSIONS: The Referral Center model provided seems to be a more efficient treatment strategy as compared with other health care facilities, as it enabled a reduction in time to transplantation. Patients treated at CRMM-HCPA demonstrated greater ease in performing social activities, with less interference from physical or emotional problems.
format Online
Article
Text
id pubmed-4595122
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45951222015-10-07 Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study Saccilotto, Indara C. Bittencourt, Rosane Isabel Fischer, Camila C. Quevedo, Amanda Hirakata, Vania N. Picon, Paulo D. BMC Health Serv Res Research Article BACKGROUND: Within the Brazilian Unified Health System (SUS), Referral Centers (RCs) are care facilities that provide specialized services. The objective of this study was to evaluate the efficacy of care provided to patients with multiple myeloma (MM) at a specialized RC (Hospital de Clínicas de Porto Alegre Referral Center for Multiple Myeloma, CRMM-HCPA) and to compare quality of life between patients with MM treated at CRMM-HCPA and those treated at non-RC facilities. METHODS: A 6-month cohort study was conducted in patients with MM receiving thalidomide from the Rio Grande do Sul State Health Department and treated at CRMM-HCPA and patients receiving treatment at other, non-RC care facilities. Thirty-two patients were included in the study, 19 from CRMM-HCPA and 13 from other institutions. To analyze the efficacy of care provided at CRMM-HCPA, the main outcome measure was the time from diagnosis to referral for autologous hematopoietic stem cell transplantation (HSCT). This outcome measure was assessed using questionnaires specifically designed for this study. Quality of life was also assessed, using the SF-36 questionnaire. RESULTS: Time from MM diagnosis to referral for autologous HSCT in each group was measured only in patients aged ≤ 65 years (n = 25); of these, 15 were recruited from CRMM-HCPA and 10 from other institutions. In this analysis, there was a significant difference (p = 0.036) in time elapsed between diagnosis and referral for autologous HSCT, which was significantly shorter for patients treated at CRMM-HCPA (median, 9 months; IQR, 8.5–14.5) than for those treated elsewhere (median, 24 months; IQR, 16–24). On quality of life analysis, there was a significant difference in the Social Functioning domain of the SF-36 questionnaire, which relates to performance of social activities (p = 0.02). CONCLUSIONS: The Referral Center model provided seems to be a more efficient treatment strategy as compared with other health care facilities, as it enabled a reduction in time to transplantation. Patients treated at CRMM-HCPA demonstrated greater ease in performing social activities, with less interference from physical or emotional problems. BioMed Central 2015-10-05 /pmc/articles/PMC4595122/ /pubmed/26438377 http://dx.doi.org/10.1186/s12913-015-1123-6 Text en © Saccilotto et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Saccilotto, Indara C.
Bittencourt, Rosane Isabel
Fischer, Camila C.
Quevedo, Amanda
Hirakata, Vania N.
Picon, Paulo D.
Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study
title Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study
title_full Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study
title_fullStr Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study
title_full_unstemmed Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study
title_short Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study
title_sort efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595122/
https://www.ncbi.nlm.nih.gov/pubmed/26438377
http://dx.doi.org/10.1186/s12913-015-1123-6
work_keys_str_mv AT saccilottoindarac efficacyofareferralcenterforpatientcenteredcareinmultiplemyelomaacohortstudy
AT bittencourtrosaneisabel efficacyofareferralcenterforpatientcenteredcareinmultiplemyelomaacohortstudy
AT fischercamilac efficacyofareferralcenterforpatientcenteredcareinmultiplemyelomaacohortstudy
AT quevedoamanda efficacyofareferralcenterforpatientcenteredcareinmultiplemyelomaacohortstudy
AT hirakatavanian efficacyofareferralcenterforpatientcenteredcareinmultiplemyelomaacohortstudy
AT piconpaulod efficacyofareferralcenterforpatientcenteredcareinmultiplemyelomaacohortstudy